Shire Human Genetic Therapies Signs Exclusive Marketing and Distribution Deal With Samaritan Pharmaceuticals, Inc. to Launch REPLAGAL for Fabry Disease in Greece and Cyprus

Published: May 22, 2007

LAS VEGAS, May 22, 2007 (PRIME NEWSWIRE) -- Samaritan Pharmaceuticals Inc. (AMEX:LIV) a developer of innovative drugs, is pleased to announce it has signed a second exclusive marketing and distribution agreement, with Shire Human Genetic Therapies AB to launch and sell REPLAGAL(r) (agalsidase alfa), a European approved drug, for Fabry Disease, in Greece and Cyprus.

Back to news